19 results about "Heparin-DHE" patented technology

The invention relates to the technical field of biology, in particular to an M-MLV reverse transcriptase mutant and a preparation method and application thereof. The invention provides an M-MLV reverse transcriptase mutant as well as a preparation method and application thereof. The M-MLV reverse transcriptase mutant fuses the structural characteristics of a plurality of mutant variants, and has better performance in the aspects of reverse transcription activity and thermal stability. Particularly, the M-MLV reverse transcriptase mutant Super RT with the amino acid sequence shown as SEQ ID NO.01 has high continuous synthesis capacity and can be used for carrying out a good reverse transcription reaction on a long-chain RNA template; the method has the advantages that the cDNA can be synthesized in a complex reaction environment, and the synthesis of the full-length cDNA can be completed in a relatively short time even in the presence of common inhibitors such as guanidine salt, heparin and salt.

The application discloses a kind of postharvest fruit and vegetable chlorosis delaying composite preservative and method, the effective component of the composite preservative includes the concentration of 10-60ppm chondroitin sulfate, the concentration of 10-60ppm heparin and the concentration of 10-60ppm hyaluronic acid.The application uses chondroitin sulfate, heparin and hyaluronic acid as composite preservative to treat postharvest citron, and shows synergistic effect of delaying chlorophyll content reduction of citron, inhibiting fruit chlorosis, so as to effectively delay postharvest citron shelf life, and the composite preservative of the application has the characteristics of green and efficient, effective components can be completely water-soluble, and environmental pollution cannot be generated.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

The invention provides a coating for the surface of a medical material, a preparation method and application of the coating and the medical material.The preparation method comprises the following steps that dopamine and a polyamino compound are co-deposited on the surface of the medical material, and an adhesive layer with amino is formed on the surface of the medical material; heparin and hyaluronic acid are mixed, and carboxyl groups of heparin and hyaluronic acid are activated; and contacting the aminated medical material with the carboxyl activated heparin and hyaluronic acid, so that the amino group on the surface of the medical material and the carboxyl activated by the heparin and the hyaluronic acid are subjected to a covalent grafting reaction, and the coating for the surface of the medical material is prepared. The coating has high-efficiency anticoagulation and anti-inflammatory dual biological activities, and has excellent stability.

The present invention provides an anticoagulant reversal agent which is a compound having the structure represented by formula I, a salt thereof, or a deuterated thereof. Experimental results have shown that the compound according to the present invention can more effectively suppress hemorrhagic complications caused by anticoagulants such as warfarin, heparin, and enoxaparin sodium, and exhibits high efficacy over a broad spectrum.

The invention relates to a composition for stabilizing a human prothrombin complex and application of the composition. The composition comprises an anticoagulant and a protective agent, the anticoagulant is heparin and / or a pharmaceutically acceptable salt thereof; the protective agent is selected from arginine and / or histidine and one or more of their respective pharmaceutically acceptable salts, and the ratio of the anticoagulant to the protective agent is (4.5-9.5) IU: (0.02-0.04) g. The activity of FII, FVII, FIX and FX of the prothrombin complex preparation prepared by adopting the composition for stabilizing the human prothrombin complex provided by the invention is not obviously reduced even under the condition of high temperature (40 + / -2 DEG C), and the activity of the FII, the FVII, the FIX and the FX is not obviously reduced after the prothrombin complex preparation is stored at the high temperature for at least 24 months. The biological activity index of the prothrombin complex preparation still meets the clinical use standard.

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

The invention discloses a cationic fluorescent probe with long wavelength emission as well as a preparation method and application of the cationic fluorescent probe. The fluorescent probe disclosed by the invention has the characteristic of emitting red fluorescence, the probe is combined with heparin through electrostatic interaction, and the fluorescence is quenched, so that the heparin is detected; furthermore, the protamine is specifically combined with the heparin, probe molecules are released, fluorescence is recovered, and the protamine is detected; the long-wavelength fluorescent probe provided by the invention has good selectivity and sensitivity on heparin and protamine, and can be applied to a serum dilution environment.

The invention relates to the technical field of heparin and protamine analysis, in particular to a method for determining the dosage of heparin and protamine. The method comprises the steps that a first sample set A is obtained, Ai is the ith first sample, and Ai is obtained by adding different doses of preset chemical substances into a blood sample of a target individual; acquiring a whole blood activation blood coagulation time detection result set B; obtaining a target model according to the whole blood activation coagulation time detection result in the step B, the dosage of the corresponding added preset chemical substance and the preset model; and according to the target whole blood activated coagulation time and the target model, obtaining the dosage of a preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual. According to the method, the heparin dosage and the protamine dosage which are suitable for the target individual and correspond to the target whole blood activation coagulation time can be determined, and reference is provided for the heparin dosage and the protamine dosage in an actual application scene.

Disclosed herein are compositions and methods for treatment or prevention of a respiratory viral infection. A composition of the present disclosure comprises one or more of heparin, or N-acetylcysteine. A composition for treatment or prevention of a respiratory viral infection may be administered by inhalation in intervals. Administration of a composition may treat or prevent a viral infection.

The application relates to the technical field of heparin and protamine analysis, in particular to a heparin and protamine dose determination method. The method comprises the following steps: obtaining a first sample set A, wherein A i is the ith first sample, A i is obtained by adding different doses of a preset chemical substance in a blood sample of a target individual; obtaining a whole blood activated coagulation time detection result set B; obtaining a target model according to the whole blood activated coagulation time detection result in B, the dose of the corresponding added preset chemical substance and a preset model; and obtaining the dose of the preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual according to the target whole blood activated coagulation time and the target model. The application can determine the heparin dose and the protamine dose suitable for the target individual and corresponding to the target whole blood activated coagulation time, and provides a reference for the heparin dose and the protamine dose in an actual application scene.

The invention belongs to the technical field of biomedical materials, and particularly relates to a skin wound bionic dressing and a preparation method thereof. The dressing comprises an upper barrier layer, a middle functional layer and a lower diversion layer which are sequentially cross-linked and stacked, the functional layer is a drug-loaded nanofiber membrane loaded with heparin and a vanillin-polymer conjugate, vanillin is connected with a polymer through a pH sensitive hydrazone bond, and intelligent drug release in an infected microenvironment can be realized; the flow guide layer is hydrogel with a vertical orientation porous structure, and excessive seepage can be rapidly and directionally guided out; the barrier layer is photo-crosslinked methacrylated gelatin hydrogel, silver-loaded mesoporous silica nanoparticles are dispersed in the barrier layer, and mechanical protection and long-acting antibiosis are provided; the multi-layer structure of the bionic skin integrates rapid seepage management, pH response drug controlled release and multiple antibacterial functions, effectively promotes wound healing, and has excellent clinical application prospects.

The invention discloses preparation and application of an anti-fouling, anti-coagulation and thrombolysis multifunctional zwitterionic hydrogel composite coating. The composite coating is composed of a mediating layer, a zwitterionic polymer hydrogel coating, heparin and urokinase. The multifunctional composite anticoagulant coating is formed through efficient combination of anti-fouling and biological inert anticoagulation of zwitterionic polymer hydrogel, biological active anticoagulation of heparin and thrombolysis of fibrinolytic factors such as urokinase. According to the method for preparing the composite coating by constructing the zwitterionic polymer hydrogel coating, regulating and controlling the number of amino groups and carboxyl groups on the surface, grafting heparin at a tip point and then fixing urokinase at a single point, biological inertia and biological activity synergistic anticoagulation and seamless connection of passive defense anticoagulation and efficient active attack thrombolysis are better realized. The method is suitable for directly constructing coatings on the surfaces of devices of different materials, shapes and sizes, and a new way is provided for long-term efficient antithrombotic modification of the surfaces of instruments needing long-term implantation.

The invention provides a composition and a method for culturing mesenchymal stem cells, the mesenchymal stem cells and application of the mesenchymal stem cells. Experiments prove that a culture medium comprising a basal culture medium, platelet lysate, heparin and a beta-FGF2 factor is suitable for culturing the mesenchymal stem cells, and a method for culturing the mesenchymal stem cells is developed on the basis of the culture medium. The mesenchymal stem cells obtained by the method disclosed by the invention are high in yield, purity and activity and have better immunosuppression capability. According to the method, the preparation cost and the damage to the cells are reduced, the high-quality mesenchymal stem cells can be obtained on a large scale through the method, and powerful support is provided for subsequent cell treatment, tissue repair and regenerative medicine application.

The present invention relates to a method for obtaining heparin, native proteins and peptides, and other compounds of interest, by fractionation of mammalian intestinal mucosa. Certain new fractions or extracts of the mucosa containing said compounds are also disclosed.

Provided herein are methods of treating or preventing venom induced injury, including local tissue damage and / or skin irritation using composition comprising an effective amount of heparin and / or heparinoid. Also provided are uses of said composition in the manufacture of a medicament for treating or preventing the same and said composition for use in treating or preventing the same.

Disclosed herein are cellular derived heparin and heparan sulfate compositions, methods of making and using, and cell lines for making and using.

The invention discloses a construction and culture method of a sarcoma organ after nasopharyngeal carcinoma radiation. The sarcoma organ is prepared from basic components as follows: Advanced DMEM / F12, Ham's F-10 Nutrient Mix, fetal calf serum, GlutaMAX, penicillin-streptomycin (double antibodies), HEPES and N-acetylcysteine; the specific factor component is prepared from bFGF (basic fibroblast growth factor), FGF-10 (fibroblast growth factor), heparin, hEGF (human epidermal growth factor) and hIGF-2 (human insulin The additive comprises the following components: B27, N2 and A83-01 of which the vitamin A is removed, hydrocortisone, SB202190 and Y-27632; by using the culture medium, in-vitro nasopharynx cancer post-radiation sarcoma tissues can be efficiently constructed into nasopharynx cancer post-radiation sarcoma organs, and the obtained tumor organs are kept consistent with original tissues in the aspects of tissue pathological structures and tumor heterogeneity.

The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.